2023 - Research.com Medicine in Germany Leader Award
2023 - Research.com Biology and Biochemistry in Germany Leader Award
Hans-Peter Hartung mainly focuses on Multiple sclerosis, Immunology, Internal medicine, Pathology and Surgery. His research on Multiple sclerosis frequently connects to adjacent areas such as Central nervous system disease. In his research on the topic of Immunology, Neuroscience, Immunotherapy and Encephalomyelitis is strongly related with Disease.
His Internal medicine research integrates issues from Gastroenterology, Placebo and Expanded Disability Status Scale. His biological study spans a wide range of topics, including Inflammation, Magnetic resonance imaging and Blood–brain barrier. He has researched Surgery in several fields, including Fingolimod, Fingolimod Hydrochloride and Polyradiculoneuropathy.
His primary areas of study are Multiple sclerosis, Immunology, Internal medicine, Pathology and Neuroscience. Hans-Peter Hartung combines subjects such as Clinical trial and Disease with his study of Multiple sclerosis. His work in Immune system, Antibody, T cell, Pathogenesis and Autoimmune disease is related to Immunology.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Placebo, Surgery and Oncology. The various areas that Hans-Peter Hartung examines in his Placebo study include Clinical endpoint and Expanded Disability Status Scale. His Pathology research incorporates elements of Peripheral nervous system and Magnetic resonance imaging.
His primary areas of investigation include Multiple sclerosis, Internal medicine, Placebo, Clinical trial and Family medicine. Multiple sclerosis is the subject of his research, which falls under Immunology. Hans-Peter Hartung mostly deals with Antibody in his studies of Immunology.
His work is dedicated to discovering how Internal medicine, Expanded Disability Status Scale are connected with Phases of clinical research and other disciplines. His Placebo study incorporates themes from Chronic inflammatory demyelinating polyneuropathy and Hazard ratio. While the research belongs to areas of Family medicine, Hans-Peter Hartung spends his time largely on the problem of Octapharma, intersecting his research to questions surrounding Double blind.
Hans-Peter Hartung mostly deals with Multiple sclerosis, Internal medicine, Placebo, Clinical endpoint and Randomized controlled trial. His biological study focuses on Natalizumab. His Internal medicine research includes elements of Gastroenterology, Interferon beta-1a and Expanded Disability Status Scale.
The concepts of his Placebo study are interwoven with issues in Data monitoring committee, BIIB033 and Negative regulator. His Clinical endpoint research is multidisciplinary, relying on both Siponimod, Multicenter trial and Intention-to-treat analysis. His study in the field of Autoimmunity is also linked to topics like Multifocal motor neuropathy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
W. Ian McDonald;Alistair Compston;Gilles Edan;Donald E Goodkin.
Annals of Neurology (2001)
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Chris H. Polman;Stephen C. Reingold;Gilles Edan;Massimo Filippi.
Annals of Neurology (2005)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson;Brenda L. Banwell;Frederik Barkhof;Frederik Barkhof;William M. Carroll.
Lancet Neurology (2017)
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Jeffrey A. Cohen;Frederik Barkhof;Giancarlo Comi;Hans Peter Hartung.
The New England Journal of Medicine (2010)
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
Giancarlo Comi;Massimo Filippi;Frederik Barkhof;Luca Durelli.
The Lancet (2001)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold.
The New England Journal of Medicine (2017)
Chemotherapy-induced peripheral neuropathy.
Stefan Quasthoff;Hans Peter Hartung.
Journal of Neurology (2002)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni.
The New England Journal of Medicine (2017)
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
Hans-Peter Hartung;Richard Gonsette;Nikolaus Konig;Hubert Kwiecinski.
The Lancet (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: